Nomura Holdings
PTGX icon

Nomura Holdings’s Protagonist Therapeutics PTGX Stock Holding History

Nomura Holdings’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,479
Closed -$1.1M – 1996
2026
Q1 		$1.1M Sell
10,479
-7,042
-40% -$624K ﹤0.01% 1120
2025
Q4 		$1.53M Buy
+17,521
New +$1.43M ﹤0.01% 1186
2025
Q3 		– Sell
-7,416
Closed -$410K – 2037
2025
Q2 		$410K Buy
+7,416
New +$356K ﹤0.01% 1175
2024
Q4 		– Sell
-8,159
Closed -$367K – 2356
2024
Q3 		$367K Buy
+8,159
New +$330K ﹤0.01% 1310

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nomura Holdings's PTGX Position: Q2 2026 in Review

Nomura Holdings sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 10,479 shares — an estimated $1.1M sold.

Nomura Holdings first reported a position in PTGX in Q3 2024 and held it in 4 quarters. The position peaked at $1.53M in Q4 2025. 316 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Nomura Holdings reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Nomura Holdings sold 10,479 Protagonist Therapeutics shares in Q2 2026, an estimated $1.1M.
  • Nomura Holdings first reported a position in Protagonist Therapeutics in Q3 2024 and held it in 4 quarters.
  • Nomura Holdings's Protagonist Therapeutics position peaked at $1.53M in Q4 2025.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.